Marek Liyanage
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marek Liyanage.
Cell | 1996
Carrolee Barlow; Shinji Hirotsune; Richard Paylor; Marek Liyanage; Michael A. Eckhaus; Francis S. Collins; Yosef Shiloh; Jacqueline N. Crawley; Thomas Ried; Danilo A. Tagle; Anthony Wynshaw-Boris
A murine model of ataxia telangiectasia was created by disrupting the Atm locus via gene targeting. Mice homozygous for the disrupted Atm allele displayed growth retardation, neurologic dysfunction, male and female infertility secondary to the absence of mature gametes, defects in T lymphocyte maturation, and extreme sensitivity to gamma-irradiation. The majority of animals developed malignant thymic lymphomas between 2 and 4 months of age. Several chromosomal anomalies were detected in one of these tumors. Fibroblasts from these mice grew slowly and exhibited abnormal radiation-induced G1 checkpoint function. Atm-disrupted mice recapitulate the ataxia telangiectasia phenotype in humans, providing a mammalian model in which to study the pathophysiology of this pleiotropic disorder.
Journal of Molecular Medicine | 1997
Thomas Ried; Marek Liyanage; Stan du Manoir; Kerstin Heselmeyer; Gert Auer; Merryn Macville; Evelin Schröck
Abstract Fluorescence in situ hybridization techniques allow the visualization and localization of DNA target sequences on the chromosomal and cellular level and have evolved as exceedingly valuable tools in basic chromosome research and cytogenetic diagnostics. Recent advances in molecular cytogenetic approaches, namely comparative genomic hybridization and spectral karyotyping, now allow tumor genomes to be surveyed for chromosomal aberrations in a single experiment and permit identification of tumor-specific chromosomal aberrations with unprecedented accuracy. Comparative genomic hybridization utilizes the hybridization of differentially labeled tumor and reference DNA to generate a map of DNA copy number changes in tumor genomes. Comparative genomic hybridization is an ideal tool for analyzing chromosomal imbalances in archived tumor material and for examining possible correlations between these findings and tumor phenotypes. Spectral karyotyping is based on the simultaneous hybridization of differentially labeled chromosome painting probes (24 in human), followed by spectral imaging that allows the unique display of all human (and other species) chromosomes in different colors. Spectral karyotyping greatly facilitates the characterization of numerical and structural chromosomal aberrations, therefore improving karyotype analysis considerably. We review these new molecular cytogenetic concepts, describe applications of comparative genomic hybridization and spectral karyotyping for the visualization of chromosomal aberrations as they relate to human malignancies and animal models thereof, and provide evidence that fluorescence in situ hybridization has developed as a robust and reliable technique which justifies its translation to cytogenetic diagnostics.
Oncogene | 1998
Stephen McCormack; Zoë Weaver; Sandy Deming; Geraldine Natarajan; Jeff Torri; Michael D. Johnson; Marek Liyanage; Thomas Ried; Robert B. Dickson
We have examined defects in mammary development and tumorigenesis in a transgenic model expressing the c-myc gene under the MMTV–LTR promoter. The stochastic tumors which arise from hyperplastic ductal and lobular lesions in this model are characterized by high rates both of apoptosis and of chromosomal instability. Since the p53 gene product is thought to be central in the maintenance of genomic integrity, in part due to its ability to induce apoptosis in cells harboring DNA damage, we examined its expression and possible mutation. Initially, we observed that unmutated p53 is strongly expressed in premalignant mammary glands and in mammary tumors derived from the MMTV-c-myc strain. We then mated the MMTV-myc strain to a p53-deficient strain as a means of examining the effect of this lesion on mammary development and tumorigenesis in the context of c-myc overexpression. A lack of both p53 alleles in the presence of c-myc overexpression resulted in a dramatic hyerplastic alteration in mammary gland development. Specifically, in female bitransgenic MMTV-c-myc/p53 null mice (MMTV-myc/p53−/−), lobular hyperplasias were observed at almost every ductal end bud as early as 32 days of age. In contrast, only mild ductal and lobular hyperplasias were seen in MMTV-myc mice that contained both p53 alleles (MMTV-myc/p53+/+); an intermediate phenotype occurred in mice with a single intact (MMTV-myc/p53+/−) p53 allele. Mammary carcinomas arose with a high frequency in MMTV-myc/p53+/− mice; the tumors were comparable in frequency, histology and apoptotic index to the tumors in MMTV-myc/p53+/+ mice. Also, as previously observed (), lymphomas arose with extremely short latency in MMTV-myc/ p53−/− mice, precluding study of the fate of their hyperplastic mammary lesions in situ. The frequency of p53 mutations in MMTV-myc/p53+/+ and MMTV-myc/p53+/− mammary tumors and in cell lines derived from these tumors was examined by direct sequencing. No point mutations or deletions in p53 were observed in mammary tumors or cell lines from either genotype. Finally, a detailed chromosomal analysis using multicolor spectral karyotyping (SKY) revealed that there were multiple chromosomal alterations in the c-myc-overexpressing cells that contained either one or two unmutated p53 alleles. Variable ploidy changes, a common translocation of chromosome 11, and other chromosomal aberrations were observed. Our data thus support an interaction between c-Myc and p53 in mammary development, but suggest that loss of p53 is required neither for c-myc-dependent tumorigenesis nor for c-myc-dependent chromosomal instability.
Genes, Chromosomes and Cancer | 1999
Zoë Weaver; Stephen J. McCormack; Marek Liyanage; Stan du Manoir; Allen E. Coleman; Evelin Schröck; Robert B. Dickson; Thomas Ried
Mice carrying the MMTV‐cmyc transgene develop mammary tumors at 9 to 12 months of age. Little is known about karyotypic changes in this model of human breast cancer. We have developed and applied molecular cytogenetic techniques to study chromosomal aberrations that occur in these tumors, namely, comparative genomic hybridization and spectral karyotyping. Cell lines from eight tumors were established and analyzed, four of which carried a heterozygous p53 mutation. All of the tumor cell lines revealed increases in ploidy and/or multiple numerical and structural chromosomal aberrations. No consistent differences were observed between cmyc/p53+/+ and cmyc/p53+/− tumors, suggesting that cmyc induces karyotype instability independent of p53 status. Loss of whole chromosome (Chr) 4 was detected in five of the eight tumors. Parts of Chr 4 are syntenic to human 1p31–p36, a region that is also deleted in human breast carcinomas. Four tumors carried translocations involving the distal portion of Chr 11 (syntenic to human chromosome arm 17q), including two translocations T(X;11), with cytogenetically identical breakpoints. We compare the pattern of chromosomal aberrations with human breast cancers, find similarities in several syntenic regions, and discuss the potential of an interspecies cytogenetic map of chromosomal gains and losses. Genes Chromosomes Cancer 25:251–260, 1999. Published 1999 Wiley‐Liss, Inc.
Oncogene | 1998
Min-Ling Liu; Friederike C. von Lintig; Marek Liyanage; Masa-Aki Shibata; Cheryl L. Jorcyk; Thomas Ried; Gerry R. Boss; Jeffrey E. Green
We have previously documented that transgenic mice expressing SV40 Tag regulated by the rat prostatic steroid-binding protein C3(1) 5′-flanking region display multistage mammary tumorigenesis. To delineate genetic changes associated with mammary tumor progression, comparative genomic hybridization (CGH) was performed. CGH revealed a consistent gain of the telomeric region of chromosome 6. This region contains the Ki-ras proto-oncogene. Analyses of genomic DNA by Southern blot demonstrated up to 40-fold amplification of the Ki-ras gene. Ki-ras amplification was detected in 12, 46 and 68% of tumors from 4, 5 and 6 month old mice, respectively, whereas no amplifications were found in any preneoplastic mammary tissues. Tumors bearing Ki-ras gene amplification exhibited high levels of Ki-ras RNA and protein. The over-expressed Ki-Ras protein in these tumors appeared functionally active as indicated by the elevated MAP kinase activity. These data demonstrate that while Ki-ras amplification might not be an early event, there is a strong association between Ki-ras amplification and over-expression and mammary tumor progression in this model. This study also shows that CGH is a powerful and useful technique for identifying chromosomal copy number changes during tumor progression, and that this model may provide a predictable in vivo system for studying gene amplification.
Fertility and Sterility | 2000
Dmitri Dozortsev; Allen E. Coleman; Peter Nagy; Michael P. Diamond; Alexandre N. Ermilov; Ulli Weier; Marek Liyanage; Thomas M. Reid
OBJECTIVE To investigate the arrangement of chromosomes within pronuclei-stage mouse zygotes. DESIGN In vitro study. SETTING Academic medical center. PATIENT(S) None. INTERVENTION(S) None. MAIN OUTCOME MEASURE(S) Location of major alpha-satellite DNA, centromeres, and telomeres, and relative location of chromosomes. RESULT(S) Chromosomes appeared to be oriented inward by centromeres and to be interconnected by major alpha-satellite DNA, which appeared to be the sole DNA component of the nucleoli. This chromosomal arrangement persisted throughout interphase. Chromosomal painting failed to identify chromosomal ordering within pronuclei. CONCLUSION(S) Pronuclear nucleoli are represented by alpha-satellite sequences of interconnecting chromosomes that hold all chromosomes together during interphase. Chromosomes within the pronucleus are randomly positioned relative to each other.
Nature Genetics | 1996
Marek Liyanage; Allen E. Coleman; Stan du Manoir; T. Veldman; Stephen McCormack; Robert B. Dickson; Carrolee Barlow; Anthony Wynshaw-Boris; Siegfried Janz; Johannes Wienberg; Malcolm A. Ferguson-Smith; Evelin Schröck; Thomas Ried
Development | 1998
Carrolee Barlow; Marek Liyanage; Peter B. Moens; Madalina Tarsounas; Kunio Nagashima; Kevin D. Brown; Scott T. Rottinghaus; Danilo A. Tagle; Thomas Ried; Anthony Wynshaw-Boris
Proceedings of the National Academy of Sciences of the United States of America | 1994
D. Massenburg; Joong-Soo Han; Marek Liyanage; Walter A. Patton; Sue Goo Rhee; Joel Moss; Martha Vaughan
Blood | 2000
Marek Liyanage; Zoë Weaver; Carrolee Barlow; Allen E. Coleman; Daniel G. Pankratz; Stacie M. Anderson; Anthony Wynshaw-Boris; Thomas Ried